Invivyd news ‘disappointing’ but not in model, says H.C. Wainwright
H.C. Wainwright maintains a Buy rating on Invivyd (IVVD) with a $10 price target after the FDA rejected its submission to expand Pemgarda’s ...
IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell ...
Protagonist Therapeutics price target raised to $54 from $50 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Protagonist Therapeutics (PTGX) to $54 from $50 and keeps a Buy rating ...
What is HC Wainwright’s Estimate for Prothena Q4 Earnings?
Investment analysts at HC Wainwright issued their Q4 2025 EPS estimates for Prothena in a research note issued to investors on Friday, February 21st. HC Wainwright analyst A. Fein expects that the ...
SpringWorks Therapeutics’ (SWTX) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated their buy rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX – Free Report) in a report ...
SoundHound AI, Inc. (SOUN): Among the Best Robinhood Stocks to Buy Under $20
We recently published a list of 12 Best Robinhood Stocks to Buy Under $20. In this article, we are going to take a look at ...
Investing14d
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock
On Monday, H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant ...
Investing14d
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock
On Monday, H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant ...